立体定向消融放疗或手术治疗ⅠA期非小细胞肺癌后的患者报告结局：ROSEL多中心随机试验结果
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.
作者信息
Louie Alexander V, van Werkhoven Erik, Chen Hanbo, Smit Egbert F, Paul Marinus A, Widder Joachim, Groen Harry J M, van den Borne Ben E E M, De Jaeger Katrien, Slotman Ben J, Senan Suresh
机构信息
Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands; Department of Radiation Oncology, London Regional Cancer Program, Canada.
Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.
出版信息
Radiother Oncol. 2015 Oct;117(1):44-8. doi: 10.1016/j.radonc.2015.08.011.
We report quality of life and indirect costs from patient reported outcomes from the ROSEL randomized control trial comparing stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy or SBRT) versus surgical resection for medically operable stage IA non-small cell lung cancer. ROSEL closed prematurely after accruing and randomizing 22 patients. This exploratory analysis found the global health related quality of life and indirect costs to be significantly favorable and cheaper, with SABR.
我们报告了ROSEL随机对照试验中患者报告结局的生活质量和间接成本，该试验比较了立体定向消融放疗（SABR，也称为立体定向体部放疗或SBRT）与手术切除治疗医学上可手术的IA期非小细胞肺癌的效果。在招募并随机分配22名患者后，ROSEL提前结束。这项探索性分析发现，对于SABR而言，全球健康相关生活质量和间接成本显著更好且更低。
Zotero 插件